カテゴリ： GlobalData, アメリカ, 企業調査

Stemline Therapeutics Inc (STML)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Stemline Therapeutics Inc (STML) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7600
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：62
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Stemline Therapeutics Inc (Stemline) is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pipeline comprises of SL-401, SL-701, SL-801, SL-501 and SL-101. Stemline’s SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on CSCs and tumor bulk of hematologic cancers. The company’s SL-701 is an immunotherapy designed to activate the immune system to attack tumors. Its SL-801 is a novel oral small molecule reversible inhibitor of Exportin-1. Stemline is headquartered in New York, the US.

Stemline Therapeutics Inc (STML) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Stemline Therapeutics Raises US$0.74 Million In Venture Financing 11
Partnerships 12
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 12
Licensing Agreements 13
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 13
Stemline Therapeutics Enters into Licensing Agreement with CanBas 14
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 15
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For EphA2 16
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For SL-701 17
Equity Offering 18
Stemline Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 18
Stemline Therapeutics Raises USD59.6 Million in Public Offering of Shares 19
Stemline Therapeutics Prices Public Offering of Shares for USD45 Million 21
Stemline Therapeutics Raises USD60 Million in Public Offering of Shares 23
Stemline Therapeutics Announces Full Exercise Of Underwriter’s Option For Public Offering Of Shares For US$69 Million 25
Stemline Therapeutics Completes IPO For US$38.15 Million 27
Stemline Therapeutics Inc – Key Competitors 29
Stemline Therapeutics Inc – Key Employees 30
Stemline Therapeutics Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 09, 2018: Stemline Therapeutics reports second quarter 2018 financial results 32
May 09, 2018: Stemline Therapeutics Reports First Quarter 2018 Financial Results 34
Mar 16, 2018: Stemline Therapeutics Announces Fourth Quarter 2017 Financial Results 35
Nov 09, 2017: Stemline Therapeutics Reports Third Quarter 2017 Financial Results 37
Aug 08, 2017: Stemline Therapeutics Reports Second Quarter 2017 Financial Results 38
May 10, 2017: Stemline Therapeutics Reports First Quarter 2017 Financial Results 39
Mar 16, 2017: Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results 40
Corporate Communications 41
Apr 16, 2018: Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline 41
Product News 42
12/13/2017: Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented 42
08/13/2018: Stemline Therapeutics announces that FDA accepts ELZONRIS Biologics License Application and grants Priority Review 44
06/18/2018: Stemline Therapeutics Announces Positive Clinical Data from ELZONRIS (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress 45
Product Approvals 47
Jun 25, 2018: Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS (tagraxofusp; SL-401) for the Treatment of BPDCN 47
Apr 05, 2018: Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401 48
Clinical Trials 49
Jun 15, 2018: Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress 49
Jun 14, 2018: Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress 50
May 18, 2018: Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress 51
Dec 08, 2017: Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting 52
Nov 01, 2017: Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting 53
Oct 31, 2017: Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint 54
Jun 23, 2017: Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA 55
May 18, 2017: Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association Meeting 56
Mar 23, 2017: Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN 57
Mar 16, 2017: Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results 58
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-401 59
Feb 02, 2017: Stemline Therapeutics Provides Update on Pivotal BPDCN Trial 60
Jan 05, 2017: Stemline Therapeutics Announces Positive FDA Meeting and Agreement on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stemline Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Stemline Therapeutics Raises US$0.74 Million In Venture Financing 11
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 12
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 13
Stemline Therapeutics Enters into Licensing Agreement with CanBas 14
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 15
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For EphA2 16
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For SL-701 17
Stemline Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 18
Stemline Therapeutics Raises USD59.6 Million in Public Offering of Shares 19
Stemline Therapeutics Prices Public Offering of Shares for USD45 Million 21
Stemline Therapeutics Raises USD60 Million in Public Offering of Shares 23
Stemline Therapeutics Announces Full Exercise Of Underwriter's Option For Public Offering Of Shares For US$69 Million 25
Stemline Therapeutics Completes IPO For US$38.15 Million 27
Stemline Therapeutics Inc, Key Competitors 29
Stemline Therapeutics Inc, Key Employees 30

List of Figures
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Stemline Therapeutics Inc (STML)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Enviva Partners LP (EVA)：企業の財務・戦略的SWOT分析
    Enviva Partners LP (EVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Deltex Medical Group Plc (DEMG)：企業の財務・戦略的SWOT分析
    Summary Deltex Medical Group Plc (Deltex Medical), formerly Chalkgrove Plc, is a medical device company that develops fluid management equipment and oesophageal doppler monitoring systems. The company offers products such as cardioQ-ODM+, probes, simulator, bougies, cerebral oximetry, video laryngos …
  • ShaMaran Petroleum Corp (SNM)：企業の財務・戦略的SWOT分析
    Summary ShaMaran Petroleum Corp (ShaMaran Petroleum), formerly Bayou Bend Petroleum Ltd is an independent oil and gas exploration and development company. The corporation explores, produces, and develops oil and gas assets. It holds interests and operates Atrush petroleum property located in Kurdist …
  • Mashreqbank psc：企業の戦略・SWOT・財務情報
    Mashreqbank psc - Strategy, SWOT and Corporate Finance Report Summary Mashreqbank psc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • China General Technology (Group) Holding Ltd：企業の戦略・SWOT・財務情報
    China General Technology (Group) Holding Ltd - Strategy, SWOT and Corporate Finance Report Summary China General Technology (Group) Holding Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Endonovo Therapeutics Inc (ENDV)：企業の製品パイプライン分析2018
    Summary Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The company’s products include Electroceutical Therapy a FDA-Cleared for the palliative treatment of pain and post-surgical edema and CE Marked …
  • New Carolin Gold Corp：企業の戦略・SWOT・財務分析
    New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report Summary New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • DeNA Co Ltd (2432)：企業の財務・戦略的SWOT分析
    DeNA Co Ltd (2432) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Stratos Product Development LLC-医療機器分野：企業M&A・提携分析
    Summary Stratos Product Development LLC (Stratos) is a provider of product development solutions. The company offers medical product development, and product design and strategy services. It offers services which include product strategy, research, industrial design and interaction design. The compa …
  • Inchcape plc (INCH)：企業の財務・戦略的SWOT分析
    Inchcape plc (INCH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Canaan Partners：企業のM&A・事業提携・投資動向
    Canaan Partners - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Canaan Partners Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • GMR Infrastructure Limited (GMRINFRA)-エネルギー分野：企業M&A・提携分析
    Summary GMR Infrastructure Limited (GMR), a subsidiary of GMR Enterprises Private Limited, is a holding company which undertakes various projects across airport, energy, transportation and urban infrastructure sectors. The company owns and operates Delhi's Indira Gandhi International Airport, Rajiv …
  • Ineos Group AG：企業の戦略的SWOT分析
    Ineos Group AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Neuwave Medical Inc-医療機器分野：企業M&A・提携分析
    Summary NeuWave Medical Inc (NeuWave), a subsidiary of Ethicon US LLC is a medical device company that develops and commercializes energy-based minimally invasive medical devices. Its flagship product, Certus 140 microwave ablation (coagulation) system, is a minimally invasive soft tissue ablation s …
  • United Services Automobile Association：企業の戦略・SWOT・財務情報
    United Services Automobile Association - Strategy, SWOT and Corporate Finance Report Summary United Services Automobile Association - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • World Fuel Services Corp (INT)：企業の財務・戦略的SWOT分析
    World Fuel Services Corp (INT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Helix Energy Solutions Group, Inc.：企業の戦略・SWOT・財務情報
    Helix Energy Solutions Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Helix Energy Solutions Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Royal Dutch Shell Plc (RDSA)：石油・ガス：M&Aディール及び事業提携情報
    Summary Royal Dutch Shell Plc (Shell) is an integrated oil and gas company. The company explores for and produces oil and gas from conventional fields and sources such as tight rock, shale and coal formations. Its refining and petrochemical complexes across the world add value to its upstream produc …
  • Diamond Offshore Drilling Inc (DO)-石油・ガス分野：企業M&A・提携分析
    Summary Diamond Offshore Drilling, Inc. (Diamond Offshore) is an offshore oil and gas drilling company, which provides contract drilling services to the energy industry. It operates through a fleet of offshore drilling rigs comprising semisubmersibles, jack-ups, and dynamically positioned drillships …
  • Vestas Wind Systems A/S：企業の戦略・SWOT・財務情報
    Vestas Wind Systems A/S - Strategy, SWOT and Corporate Finance Report Summary Vestas Wind Systems A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆